| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Contract asset | - | 23,363 | ||
| Cash and cash equivalents | 113,713 | 168,543 | ||
| Marketable securities | 462,404 | 401,922 | ||
| Receivable from collaboration partner | 583 | - | ||
| Prepaid expenses and other current assets | 9,724 | 8,698 | ||
| Total current assets | 586,424 | 602,526 | ||
| Marketable securities - noncurrent | 102,703 | 102,493 | ||
| Property and equipment, net | 4,100 | 4,108 | ||
| Restricted cash - noncurrent | 287 | 290 | ||
| Operating lease right-of-use asset | 8,174 | 8,589 | ||
| Total assets | 701,688 | 718,006 | ||
| Accounts payable | 5,646 | 3,249 | ||
| Accrued expenses and other payables | 22,868 | 15,397 | ||
| Deferred revenue | 14,200 | 14,688 | ||
| Operating lease liability | 2,228 | 2,173 | ||
| Total current liabilities | 44,942 | 35,507 | ||
| Deferred revenue - noncurrent | 2,788 | 5,375 | ||
| Operating lease liability - noncurrent | 8,521 | 9,106 | ||
| Total liabilities | 56,251 | 49,988 | ||
| Common stock, 0.00001 par value, 180,000,000 shares authorized 62,447,102 and 61,035,139 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 1,071,198 | 1,054,980 | ||
| Accumulated other comprehensive income (loss) | 525 | -15 | ||
| Accumulated deficit | -426,287 | -386,948 | ||
| Total stockholders' equity | 645,437 | 668,018 | ||
| Total liabilities and stockholders' equity | 701,688 | 718,006 | ||
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)